Actinium Pharmaceuticals - רווח למניה בשנים עשר החודשים האחרונים ATNM

Actinium Pharmaceuticals (ATNM) brings together leading radiobiologists to develop innovative leukemia treatments, leveraging an academic approach and R&D budgets. Net income per share over 12 months on the GURU.Markets chart captures profitability dynamics, where 0.36 reflects the most recent value of the metric. While the drug Iomab-B makes bone marrow transplantation more accessible for the elderly, the high concentration of resources on final trials creates a binary risk of regulatory dependence.
פילוחי נתונים אנליטיים מרוכזים עבור Actinium Pharmaceuticals Inc (ATNM)

Minimizing fundamental risks requires selecting assets with sustainable earnings growth. This metric is calculated by dividing the total annual net income by the total number of shares, measuring the actual return per share. For Actinium Pharmaceuticals (ATNM), this indicator reflects the efficiency of capitalizing patents in the field of cancer radiotherapy. Analyzing the rolling annual earnings per share allows for an assessment of the monetization rate of medical technologies. A stable upward trend confirms the reliability of the investment.